Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 10/20 | 1.00 |
| ▸ | PIM2 | Q9P1W9 | 10/20 | 1.00 |
| ▸ | NAT1 | P18440 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.68 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.68 |
| ▸ | GSK3B | P49841 | 1/20 | 0.68 |
| ▸ | TTR | P02766 | 2/20 | 0.63 |
| ▸ | IGF1R | P08069 | 2/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2539680 | 1.00 | PIM1 (1.00) | PIM1PIM2NAT1HPGDAKR1B1 | |
| SCHEMBL2539679 | 1.00 | PIM1 (1.00) | PIM1PIM2NAT1HPGDAKR1B1 | |
| SCHEMBL7557609 | 0.85 | NAT1 (1.00) | PIM1PIM2NAT1CISD1GSK3B | |
| SCHEMBL7557614 | 0.85 | NAT1 (1.00) | PIM1PIM2NAT1CISD1GSK3B | |
| SCHEMBL2545594 | 0.83 | PIM1 (1.00) | PIM1PIM2HPGDAKR1B1CISD1 | |
| SCHEMBL2547566 | 0.83 | PIM1 (1.00) | PIM1PIM2HPGDAKR1B1CISD1 | |
| SCHEMBL2545596 | 0.83 | PIM1 (1.00) | PIM1PIM2HPGDAKR1B1CISD1 | |
| SCHEMBL1250348 | 0.83 | PIM1 (1.00) | PIM1PIM2AKR1B1CISD1MAOA | |
| SCHEMBL2548389 | 0.83 | PIM1 (1.00) | PIM1PIM2AKR1B1CISD1MAOA | |
| SCHEMBL1250346 | 0.83 | PIM1 (1.00) | PIM1PIM2AKR1B1CISD1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | claimed |
| EP-2217235-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | Musc Foundation for Research Development (US) | 2010-08-18 | — | — | EP | claimed |
| WO-2009064486-A9 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUND FOR RES DEV (US) | 2009-07-16 | — | — | WO | claimed |
| WO-2009064486-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2009-05-22 | — | — | WO | claimed |
| EP-1214305-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | claimed |
| WO-2001016123-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-8790855-B2 | Charge control agent and toner using same | HODOGAYA CHEMICAL CO., LTD (JP) | 2014-07-29 | — | — | US | disclosed |
| US-8790855-B2 | Charge control agent and toner using same | HODOGAYA CHEMICAL CO., LTD (JP) | 2014-07-29 | — | — | US | disclosed |
| EP-2618218-A1 | CHARGE CONTROL AGENT AND TONER USING SAME | Hodogaya Chemical Co., Ltd. (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-20130177843-A1 | CHARGE CONTROL AGENT AND TONER USING SAME | HODOGAYA CHEMICAL CO., LTD. (JP) | 2013-07-11 | — | — | US | disclosed |
| US-20130177843-A1 | CHARGE CONTROL AGENT AND TONER USING SAME | HODOGAYA CHEMICAL CO., LTD. (JP) | 2013-07-11 | — | — | US | disclosed |
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2217235-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | Musc Foundation for Research Development (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20100035957-A1 | Methods for the Use of Inhibitors of Cytosolic Phospholipase A2 | WYETH | 2010-02-11 | — | — | US | disclosed |
| WO-2009064486-A9 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUND FOR RES DEV (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009064486-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2009-05-22 | — | — | WO | disclosed |
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885NAT1 3056/4885 |
| US-20100035957-A1 | Methods for the Use of Inhibitors of Cytosolic Phospholipase A2 | PLA2G4A, PLA2G4B, PLA2G1B | PIM1 1622/4885PIM2 782/4885NAT1 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.